Enterprise Value
167.4M
Cash
162.1M
Avg Qtr Burn
-43.99M
Short % of Float
11.54%
Insider Ownership
5.40%
Institutional Own.
90.37%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Seralutinib (GB002) (Inhaled PDGF receptor kinase inhibitor) Details Rare diseases, Pulmonary arterial hypertension, Lung disease | Phase 2 Data readout | |
GB004 (Oral HIF-1α stabilizer) Details Ulcerative colitis | Failed Discontinued | |
GB1275 (Oral CD11b modulator) Details Solid tumor/s, Esophageal cancer, Cancer, Gastric cancer | Failed Discontinued | |
Failed Discontinued |